Dr Kathy Gately
Senior Scientist (Translational Oncology)
Dr Kathy Gately has 20 years of experience in the area of translational oncology research including biomarker discovery, cancer molecular diagnostics and pre-clinical drug testing. Her primary research focus is drug resistance mechanisms as novel biomarkers and targets for therapy. She is Clinical Senior Lecturer, Dept. of Clinical Medicine at the Trinity Translational Medicine Institute. Dr Gately’s group identified activated PIM kinase as a key mechanism of resistance to PI3K-mTOR inhibition in non-small cell lung cancer (NSCLC) and demonstrated that co-targeting PI3K and PIM kinase is a more effective treatment strategy than single targeted treatment. Further data from Dr. Gately’s group showed for the first time that PIM kinases are activated in two parallel mechanisms of resistance to EGFR TKIs (i) MET amplification and (ii) epithelial-to-mesenchymal transition (EMT). Dr Gately is author or co-author of numerous publications relating to PI3K and PIM kinase.